SCHEMBL738443

SCHEMBL738443

Cc1ccc(-c2ncc(C)cn2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
METAP2 P50579 1/20 0.45
METAP1 P53582 1/20 0.45
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HDAC4 P56524 4/20 0.42
NFKB1 P19838 3/20 0.42
NFKB2 Q00653 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10000244 0.97 NPC1 (0.48) CCR1CCR5CCR8HDAC6METAP2
SCHEMBL13402229 0.97 NPC1 (0.48) CCR1CCR5CCR8HDAC6METAP2
SCHEMBL15599296 0.95 NPC1 (0.46) CCR1CCR5CCR8HDAC6METAP2
SCHEMBL15599291 0.95 NPC1 (0.48) CCR1CCR5CCR8HDAC6METAP2
SCHEMBL2608309 0.87 NPC1 (0.60) METAP2METAP1NPC1RAB9AMEN1
SCHEMBL12628180 0.86 ADORA3 (0.42) CCR1CCR5CCR8HDAC6METAP2
SCHEMBL12628196 0.86 ADORA3 (0.42) CCR1CCR5CCR8HDAC6METAP2
SCHEMBL17051549 0.85 NPC1 (0.46) CCR1CCR5CCR8HDAC6METAP2
SCHEMBL17055369 0.85 CLK4 (0.54) CCR1CCR5CCR8NPC1RAB9A
SCHEMBL17051539 0.84 CCR1 (0.60) CCR1CCR5CCR8HDAC6METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240241403-A1 POLARIZER AND IMAGE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2024-07-18 US disclosed
US-20230384498-A1 OPTICALLY ANISOTROPIC FILM, OPTICAL FILM, AND DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2023-11-30 US disclosed
US-20230358935-A1 OPTICAL FILM AND ELECTROLUMINESCENCE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2023-11-09 US disclosed
US-11781069-B2 Liquid-crystal medium MERCK PATENT GMBH (DE) 2023-10-10 US disclosed
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2023-09-28 US disclosed
US-11768323-B2 Polarizer and image display device FUJIFILM CORPORATION (JP) 2023-09-26 US disclosed
US-20230272282-A1 LC MIXTURES WITH NEGATIVE DELTA EPSILONCONTAINING CC-4-V1 AND COB(S)-N-OM MERCK PATENT GMBH (DE) 2023-08-31 US disclosed
US-11739267-B2 LC medium MERCK PATENT GMBH (DE) 2023-08-29 US disclosed
WO-2023146896-A1 BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS PARION SCIENCES, INC. (US) 2023-08-03 WO disclosed
US-20230242817-A1 LIQUID-CRYSTAL MEDIUM COMPRISING POYLMERIZABLE COMPOUNDS MERCK PATENT GMBH (DE) 2023-08-03 US disclosed
US-20070232610-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-10-04 US disclosed
US-7258902-B2 Chiral 3,4-dihydro-2H-pyran compounds BASF AKTIENGESELLSCHAFT (DE) 2007-08-21 US disclosed
US-7258902-B2 Chiral 3,4-dihydro-2H-pyran compounds BASF AKTIENGESELLSCHAFT (DE) 2007-08-21 US disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 US disclosed
US-7198828-B2 Liquid-crystalline medium MERCK PATENT GESELLSCHAFT (DE) 2007-04-03 US disclosed
US-7195719-B1 High polarization ferroelectric liquid crystal compositions DISPLAYTECH, INC. (US) 2007-03-27 US disclosed
US-7195719-B1 High polarization ferroelectric liquid crystal compositions DISPLAYTECH, INC. (US) 2007-03-27 US disclosed
EP-0031796-B1 4-HETEROCYCLYL-4'-VINYL-STILBENES CIBA-GEIGY AG (CH) 1985-01-23 EP disclosed
US-4366189-A WHITENERS CIBA-GEIGY CORPORATION (US) 1982-12-28 US disclosed
EP-0031796-A2 4-Heterocyclyl-4'-vinyl-stilbenes CIBA-GEIGY AG (CH) 1981-07-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191604-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 CCR1 3818/4885CCR5 3112/4885CCR8 4699/4885
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, OPRL1 CCR1 585/4885CCR5 966/4885CCR8 62/4885
US-20070232610-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 CCR1 3818/4885CCR5 3112/4885CCR8 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.